Literature DB >> 19277871

Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making.

Kristin C Carlsson1, Radojka M Savić, Andrew C Hooker, Mats O Karlsson.   

Abstract

In nonlinear mixed effects modeling using NONMEM, mixture models can be used for multimodal distributions of parameters. The fraction of individuals belonging to each of the subpopulations can be estimated, and the most probable subpopulation for each patient is output (MIXEST(k)). The objective function value (OFV) that is minimized is the sum of the OFVs for each patient (OFV(i)), which in turn is the sum across the k subpopulations (OFV(i,k)). The OFV(i,k) values can be used together with the total probability in the population of belonging to subpopulation k to calculate the individual probability of belonging to the subpopulation (IP(k)). Our objective was to explore the information gained by using IP(k) instead of or in addition to MIXEST(k) in the analysis of mixture models. Two real data sets described previously by mixture models as well as simulations were used to explore the use of IP(k) and the precision of individual parameter values based on IP(k) and MIXEST(k). For both real data-based mixture models, a substantial fraction (11% and 26%) of the patients had IP(k) values not close to 0 or 1 (IP(k) between 0.25 and 0.75). Simulations of eight different scenarios showed that individual parameter estimates based on MIXEST were less precise than those based on IP(k), as the root mean squared error was reduced for IP(k) in all scenarios. A probability estimate such as IP(k) provides more detailed information about each individual than the discrete MIXEST(k). Individual parameter estimates based on IP(k) should be preferable whenever individual parameter estimates are to be used as study output or for simulations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277871      PMCID: PMC2664892          DOI: 10.1208/s12248-009-9093-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  11 in total

1.  Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection.

Authors:  S Sadray; E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

2.  Population pharmacokinetics of perhexiline from very sparse, routine monitoring data.

Authors:  R Hussein; B G Charles; R G Morris; R L Rasiah
Journal:  Ther Drug Monit       Date:  2001-12       Impact factor: 3.681

3.  Software for population pharmacokinetics and pharmacodynamics.

Authors:  L Aarons
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

4.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

5.  Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations.

Authors:  Vladimir Piotrovsky; Achiel Van Peer; Nancy Van Osselaer; Martin Armstrong; Jeroen Aerssens
Journal:  J Clin Pharmacol       Date:  2003-05       Impact factor: 3.126

6.  Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability.

Authors:  Mary E Spilker; Kok-Yong Seng; Amy A Yao; Heike E Daldrup-Link; David M Shames; Robert C Brasch; Paolo Vicini
Journal:  J Magn Reson Imaging       Date:  2005-10       Impact factor: 4.813

7.  Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients.

Authors:  Per-Henrik Zingmark; Marianne Ekblom; Tomas Odergren; Tim Ashwood; Patrick Lyden; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

8.  Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach.

Authors:  Takahiko Tanigawa; Roland Heinig; Yoshihiro Kuroki; Shun Higuchi
Journal:  Drug Metab Pharmacokinet       Date:  2006-02       Impact factor: 3.614

9.  Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures.

Authors:  Raymond Miller; Bill Frame; Brian Corrigan; Paula Burger; Howard Bockbrader; Elizabeth Garofalo; Richard Lalonde
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

10.  Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients.

Authors:  B Facca; B Frame; S Triesenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  19 in total

1.  A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Authors:  Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

2.  Adjustment of the area under the concentration curve by terminal rate constant for bioequivalence assessment in a parallel-group study of lamotrigine.

Authors:  Jiansong Yang; Peiming Ma; Jonathan Bullman; Andrew Nicholls; Chao Chen
Journal:  Br J Clin Pharmacol       Date:  2019-01-17       Impact factor: 4.335

Review 3.  Pharmacodynamic models for discrete data.

Authors:  Ines Paule; Pascal Girard; Gilles Freyer; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

4.  Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.

Authors:  Zinnia P Parra-Guillen; Pedro Berraondo; Emmanuel Grenier; Benjamin Ribba; Iñaki F Troconiz
Journal:  AAPS J       Date:  2013-04-19       Impact factor: 4.009

5.  Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin.

Authors:  Nelleke Snelder; Henk-Jan Drenth; Kirsten Riber Bergmann; Nolan David Wood; Mark Hibberd; Graham Scott
Journal:  Br J Clin Pharmacol       Date:  2019-04-03       Impact factor: 4.335

6.  Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.

Authors:  V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

7.  Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.

Authors:  Denise Morris; Joseph Podolski; Alan Kirsch; Ronald Wiehle; Lawrence Fleckenstein
Journal:  AAPS J       Date:  2011-10-25       Impact factor: 4.009

8.  Population Pharmacokinetic Modelling for Estimation of Remifentanil Metabolic-Ratio Using Non-steady-State Concentrations under Rapidly Adaptive Dosing.

Authors:  Monica Simeoni; Chao Chen
Journal:  Pharm Res       Date:  2018-09-25       Impact factor: 4.200

9.  Quantifying the Pharmacodynamics of Morphine in the Treatment of Postoperative Pain in Preverbal Children.

Authors:  Sebastiaan C Goulooze; Tirsa de Kluis; Monique van Dijk; Ilse Ceelie; Saskia N de Wildt; Dick Tibboel; Elke H J Krekels; Catherijne A J Knibbe
Journal:  J Clin Pharmacol       Date:  2021-09-17       Impact factor: 2.860

10.  A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.

Authors:  Stijn W van Beek; Rob Ter Heine; Jan-Willem C Alffenaar; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2021-02-22       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.